öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÍõÓÀ¾ü
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º131

ËùÊôԺУ£ºÉòÑôÒ©¿Æ´óѧ
ËùÊôԺϵ£ºÎÞÑÄѧԺ
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼/²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©¼Áѧ¡¢Ò©Ñ§£¨Ò©¼Áѧ·½Ïò£©
Ñо¿ÁìÓò£º Ò»£º¾ßÓÐÁ¼ºÃ³ÉÒ©ÐÔÄÉÃ×Ò©ÎïÖƼÁµÄ»ù´¡Ñо¿Ó뿪·¢£¬°üÀ¨¸ßÔØÒ©Á¿Ç°Ò©×Ô×é×°Ìåϵ¡¢Ö÷¶¯ÔØÒ©Ö¬ÖÊÌå... [Õ¹¿ª]


Ñо¿ÁìÓò£º Ò»£º¾ßÓÐÁ¼ºÃ³ÉÒ©ÐÔÄÉÃ×Ò©ÎïÖƼÁµÄ»ù´¡Ñо¿Ó뿪·¢£¬°üÀ¨¸ßÔØÒ©Á¿Ç°Ò©×Ô×é×°Ìåϵ¡¢Ö÷¶¯ÔØÒ©Ö¬ÖÊÌå¡¢¸ßÔØÒ©Á¿Ö¬·¾ÈéµÈÑо¿·½Ïò¶þ£º×ªÔËÌå½éµ¼¿¹°©Ç°Ò©µÄÉè¼ÆÓ뿪·¢Ñо¿·½ÏòÈý£º³¤Ð§×¢ÉäÖƼÁµÄ¿ª·¢ [ÊÕÆð]




ͨѶ·½Ê½ :
°ì¹«µç»°£º**
µç×ÓÓʼþ£ºwangyjspu@163.com
ͨѶµØÖ·£ºÉòÑôÊÐÉòºÓÇøÎÄ»¯Â·103ºÅ112ºÅÐÅÏä


¸öÈ˼òÊö :
ÍõÓÀ¾ü£¬ÄУ¬½ÌÊÚ£¬²©Ê¿Éúµ¼Ê¦¡£2000Äê±ÏÒµÓÚɽ¶«Ò½¿Æ´óѧҩѧԺ£¬»ñҩѧѧʿѧ룬2007Äê»ñÉòÑôÒ©¿Æ´óѧҩ¼Áѧ²©Ê¿Ñ§Î»£¬ºóÁôУÈνÌ¡£2011Äê½úÉý¸±½ÌÊÚ£¬2012Äê1ÔÂÖÁ2013Äê9ÔÂÃÀ¹úUniversity of North Carolina at Chapel Hill·Ö×ÓÒ©¼Áϵ·ÃÎÊѧÕߣ¬2016Äê½úÉýΪÎÞÑÄѧԺ½ÌÊÚ¡£2015ÄêÈëÑ¡ÁÉÄþÊ¡°ÙǧÍòÈ˲Ź¤³Ì°ÙÈ˲ã´Î¡£Ö÷½²±¾¿Æ¡¶ÉúÎïÒ©¼ÁѧÓëÒ©ÎﶯÁ¦Ñ§¡·¼°Ñо¿Éú¡¶ÄÉÃ×Ò©ÎïµÝËÍϵͳ¡·¿Î³Ì¡£¿ÎÌâÑо¿·½ÏòΪ£º¾ßÓÐÁ¼ºÃ³ÉÒ©ÐÔÄÉÃ×Ò©ÎïÖƼÁµÄ»ù´¡Ñо¿Ó뿪·¢£¬°üÀ¨¸ßÔØÒ©Á¿Ç°Ò©×Ô×é×°Ìåϵ¡¢Ö÷¶¯ÔØÒ©Ö¬ÖÊÌå¡¢¸ßÔØÒ©Á¿Ö¬·¾ÈéµÈ£»×ªÔËÌå½éµ¼¿¹°©Ç°Ò©µÄÉè¼ÆÓ뿪·¢£»³¤Ð§×¢ÉäÖƼÁµÄ¿ª·¢¡£Ö÷³Ö¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿¡¢ÁÉÄþÊ¡¿Æ¼¼ÌüÏîÄ¿¡¢ÁÉÄþÊ¡½ÌÓýÌüÏîÄ¿¡¢°ÙǧÍòÈ˲Ź¤³Ì×ÊÖúÏîÄ¿µÈ¶àÏî¿ÎÌâ¡£ÔÚNano Letters¡¢Biomacromolecules¡¢Molecular Pharmaceutics¡¢ACS Applied Materials&Interfaces¡¢Scientific Reports¡¢Nanomedicine: Nanotechnology, Biology and MedicineµÈÆÚ¿¯·¢±íSCIÂÛÎÄ30Óàƪ£¬³ö°æרÖø5²¿£¬ÉêÇë¹ú¼Ò·¢Ã÷רÀû15Ïî¡£

¿ÆÑй¤×÷ :
1. Xiangfei Han, et al. Paclitaxel-paclitaxel Prodrug Nanoassembly as a Versatile Nanoplatform for Combinational Cancer Therapy, ACS Applied Materials & Interfaces, 2016, 8(49),33506-33513£¨IF=7.145£©2. Guolian Ren, et al. A unique highly hydrophobic anticancer prodrug self-assembled nanomedicine for cancer therapy,Nanomedicine: Nanotechnology, Biology and Medicine, 2016,12:2273-2282(IF=5.671)3. Peng Xue, et al. Redox-sensitive citronellol-cabazitaxel conjugate: maintained in vitro cytotoxicity and self-assembled as multifunctional nanomedicine, Bioconjugate Chemistry, 2016,27(5):1360-72(IF=4.5)4. Guolian Ren, et al.Docetaxel prodrug liposomes for tumor therapy: characterization, in vitro and in vivo evaluation, Drug Delivery,2016, 23(4):1272-81(IF=4.843)5. Jing Wang, et al. Comparison of two kinds of docetaxel-vitamin E prodrugs: in vitro evaluation and in vivo antitumor activity,International Journal of Pharmaceutics, 2016, 505(1-2):352-60(IF=3.994)6. Qiang Fu, et al. Programmed Hydrolysis in Designing Paclitaxel Prodrug for NanocarrierAssemby, Scientific Reports, 2015, 5,12023:1-10 (IF=5.228)7. Yongjun Wang, et al. Molecular-matched materials for anticancer drug delivery and imaging, Nanomedicine(Lond.), 2015,10(19):3003¨C3013(IF=5.413)8. Yongjun Wang, et al. Disulfide Bond Bridge Inse rtion Turns Hydrophobic Anticancer Prodrugs into Self-Assembled Nanomedicines. Nano Letters. 201414:5577-5583.£¨IF=13.592£©9. Yongjun Wang, et al. Shape-Controlled Paclitaxel Nanoparticles with Multiple Morphologies: Rod-Shaped, Worm-Like, Spherical, and Fingerprint-Like. Molecular pharmaceutics. 2014.£¨IF=4.78£©10. Jingling Tang, et al. Key structure of brij for overcoming multidrug resistance in cancer. Biomacromolecules. 201314:424-430.£¨IF=5.78£©Ö÷±à»ò²Î±àµÄ½Ì²Ä¡¢×¨Öø1.¹¤ÒµÒ©¼Áѧ£¬²Î±à£¬ÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2014Äê2.ҩѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØÂÛÎÄ׫дҪÇóÓë·¶Àý£¬²Î±à£¬ÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2012Äê3.ÄÉÃ×Á£¸øҩϵͳ£¬Ö÷Ò룬¿Æѧ³ö°æÉ磬2011Äê4.Ò©¼Áѧ£¬²Î±à£¬ÉϺ£¿Æѧ¼¼Êõ³ö°æÉ磬2011Äê5.»·ºý¾«°üºÏÎï¼¼Êõ£¬²Î±à£¬ÈËÃñÎÀÉú³ö°æÉ磬2008Äê